• AAPL 189.82
  • TSLA 177.46
  • AMZN 184.7
  • MSFT 420.21
  • INTC 31.85
  • EURUSD 1.0872
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. ABVX.NASDAQ

Abivax SA American Depositary Shares (ABVX NASDAQ) stock market data APIs

$14 0.36(2.6%) as of May 17, 2024

Abivax SA American Depositary Shares Financial Data Overview

13.64
14
-
14.005
13.61
7.995-17.02
705 M
62 918 K
20 000
0
1.369
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ABVX',
Type: 'Common Stock',
Name: 'Abivax SA American Depositary Shares',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG01JLQNZ03',
ISIN: NULL,
CUSIP: NULL,
CIK: '1956827',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2023-10-20',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Abivax SA American Depositary Shares Fundamental Data is available in our Financial Data APIs

  • Net Revenue 20 000
  • EBITDA -73 350 000
  • Earnings Per Share -2.66
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Abivax SA American Depositary Shares Earnings via APIs

  • Latest Release 2024-02-06
  • EPS/Forecast -0.92

Get Abivax SA American Depositary Shares End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Abivax SA American Depositary Shares latest news via APIs

Abivax Reports Excellent One-Year Efficacy and Safety Data of ABX464 Phase 2b Maintenance Trial in Ulcerative Colitis

Interim analysis demonstrates best-in-class clinical remission in 55.3% of 217 ulcerative colitis (UC) patients (full analysis set) after 48 weeks of once-daily oral 50mg ABX464 Moreover, in the subgr...
  • ABX464 PHASE 2B
  • EURONEXT PARIS
  • MAINTENANCE
  • MAINTENANCE STUDY
  • MAYO SCORE
  • PHASE 2B
  • REMISSION
  • UC
  • ULCERATIVE COLITIS

Abivax Reports 2021 Financial Results and Operations Update

Feedback received from the US and European regulatory agencies, both supporting the advancement ABX464 into a phase 3 clinical program in ulcerative colitis (UC), final preparations for the launch of ...
  • ABIVAX SA
  • CHRONIC INFLAMMATORY DISEASES
  • CLINICAL DEVELOPMENT
  • EURONEXT PARIS
  • INFLAMMATORY DISEASE
  • INFLAMMATORY DISEASES
  • UC
  • ULCERATIVE COLITIS
Do you have any questions?
support@eodhistoricaldata.com